» Articles » PMID: 39370518

Biomimetic Nanocarriers in Cancer Therapy: Based on Intercellular and Cell-tumor Microenvironment Communication

Overview
Publisher Biomed Central
Specialty Biotechnology
Date 2024 Oct 6
PMID 39370518
Authors
Affiliations
Soon will be listed here.
Abstract

Inspired by the concept of "natural camouflage," biomimetic drug delivery systems have emerged to address the limitations of traditional synthetic nanocarriers, such as poor targeting, susceptibility to identification and clearance, inadequate biocompatibility, low permeability, and systemic toxicity. Biomimetic nanocarriers retain the proteins, nucleic acids, and other components of the parent cells. They not only facilitate drug delivery but also serve as communication media to inhibit tumor cells. This paper delves into the communication mechanisms between various cell-derived biomimetic nanocarriers, tumor cells, and the tumor microenvironment, as well as their applications in drug delivery. In addition, the additional communication capabilities conferred on the modified biomimetic nanocarriers, such as targeting and environmental responsiveness, are outlined. Finally, we propose future development directions for biomimetic nanocarriers, hoping to inspire researchers in their design efforts and ultimately achieve clinical translation.

Citing Articles

Innovative Nanomedicine Delivery: Targeting Tumor Microenvironment to Defeat Drug Resistance.

Meng W, Huang L, Guo J, Xin Q, Liu J, Hu Y Pharmaceutics. 2025; 16(12.

PMID: 39771528 PMC: 11728492. DOI: 10.3390/pharmaceutics16121549.

References
1.
Chen H, Deng J, Yao X, He Y, Li H, Jian Z . Bone-targeted erythrocyte-cancer hybrid membrane-camouflaged nanoparticles for enhancing photothermal and hypoxia-activated chemotherapy of bone invasion by OSCC. J Nanobiotechnology. 2021; 19(1):342. PMC: 8549398. DOI: 10.1186/s12951-021-01088-9. View

2.
Zhu Z, Zhai Y, Hao Y, Wang Q, Han F, Zheng W . Specific anti-glioma targeted-delivery strategy of engineered small extracellular vesicles dual-functionalised by Angiopep-2 and TAT peptides. J Extracell Vesicles. 2022; 11(8):e12255. PMC: 9451528. DOI: 10.1002/jev2.12255. View

3.
Hu S, Ma J, Su C, Chen Y, Shu Y, Qi Z . Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis. Acta Biomater. 2021; 135:567-581. DOI: 10.1016/j.actbio.2021.09.003. View

4.
Shojaei S, Moradi-Chaleshtori M, Paryan M, Koochaki A, Sharifi K, Mohammadi-Yeganeh S . Mesenchymal stem cell-derived exosomes enriched with miR-218 reduce the epithelial-mesenchymal transition and angiogenesis in triple-negative breast cancer cells. Eur J Med Res. 2023; 28(1):516. PMC: 10647065. DOI: 10.1186/s40001-023-01463-2. View

5.
Hatami Z, Hashemi Z, Eftekhary M, Amiri A, Karpisheh V, Nasrollahi K . Natural killer cell-derived exosomes for cancer immunotherapy: innovative therapeutics art. Cancer Cell Int. 2023; 23(1):157. PMC: 10403883. DOI: 10.1186/s12935-023-02996-6. View